Novartis AG ADR
$ 156.33
1.37%
07 Aug - close price
- Market Cap 297,138,749,000 USD
- Current Price $ 156.33
- High / Low $ 156.68 / 155.38
- Stock P/E 23.65
- Book Value 21.86
- EPS 6.61
- Next Earning Report 2026-10-27
- Dividend Per Share $4.67
- Dividend Yield 3.07 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.30 %
- 52 Week High 165.43
- 52 Week Low 114.07
About
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Analyst Target Price
$155.37
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-21 | 2026-04-28 | 2026-02-04 | 2025-10-28 | 2025-07-17 | 2025-04-29 | 2025-01-31 | 2024-10-29 | 2024-07-18 | 2024-04-23 | 2024-01-31 | 2023-10-24 |
| Reported EPS | 2.41 | 1.65 | 2.03 | 2.25 | 2.42 | 2.28 | 1.98 | 2.06 | 1.97 | 1.8 | 1.53 | 1.74 |
| Estimated EPS | 2.2 | 1.65 | 2 | 2.31 | 2.37 | 2.17 | 1.76 | 1.93 | 1.86 | 1.68 | 1.66 | 1.74 |
| Surprise | 0.21 | 0 | 0.03 | -0.06 | 0.05 | 0.11 | 0.22 | 0.13 | 0.11 | 0.12 | -0.13 | 0 |
| Surprise Percentage | 9.5455% | 0% | 1.5% | -2.5974% | 2.1097% | 5.0691% | 12.5% | 6.7358% | 5.914% | 7.1429% | -7.8313% | 0% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-27 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 2.2 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Apr 2025 | Apr 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-16 | 2025-04-25 | 2024-04-19 | 2023-03-20 | 2022-03-17 | 2021-03-15 | None | None | None | None |
| Amount | $4.772961 | $3.99399 | $3.7395445 | $3.4693612 | $3.3574492 | $3.3783783 | $3.0424917 | $2.865 | $2.977 | $2.717759 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVS
2026-08-06 23:09:49
The FDA has approved Novartis's Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), significantly expanding its eligible patient population. This approval is based on the PSMAddition trial, which showed Pluv
2026-08-06 19:10:35
Novartis Ag reported strong Q2 2026 earnings, beating analyst expectations with an EPS of $2.41 and revenue of $14.42 billion. The company reaffirmed its full-year guidance, driven by robust performance from priority brands like KISQALI, LEQVIO, and Scemblix, and significant progress in its pipeline and regulatory milestones. Despite some near-term headwinds from generic erosion and margin pressure, the overall sentiment for the company's outlook is positive due to strong product momentum and capital returns.
2026-08-05 18:11:05
Segall Bryant & Hamill LLC acquired a new stake of 18,792 shares in Novartis AG (NVS) during the first quarter, valued at approximately $2.93 million. This purchase contributes to the 13.12% ownership of Novartis stock by institutional investors and hedge funds. Novartis recently reported quarterly revenue of $14.95 billion and earnings of $2.41 per share, with analysts maintaining a "Hold" rating and an average price target of $141.20.
2026-08-04 07:09:50
Novartis AG (NVS) is a global pharmaceutical leader with a market cap of $296.8 billion, known for its stable market position and innovative pipeline. The company offers an attractive 3.04% dividend yield with a 71.60% payout ratio, making it appealing to income-focused investors. While analyst sentiment is varied, technical indicators suggest bullish momentum, though the stock is currently in overbought territory.
2026-08-03 17:11:21
The FDA has approved Novartis' Pluvicto for an earlier stage of metastatic hormone-sensitive prostate cancer, significantly expanding the eligible patient population. This approval is based on the Phase 3 PSMAddition study, which showed a substantial reduction in disease progression or death when Pluvicto was combined with standard care. Novartis anticipates meeting the increased demand with its five U.S. manufacturing facilities.
2026-08-02 03:10:12
Novartis Ag (0K9E) released its Q4 2023 earnings report, missing both EPS and revenue expectations. The company reported actual EPS of $1.53 against a consensus of $1.65, and actual revenue of $11.62 billion compared to an expected $11.88 billion. An audio recording of the earnings call and the slide deck are available, with the next earnings date estimated for October 27, 2026.
